Objective: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). Methods: We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD. Results: Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio 5 1.58, P < .0001) versus hydrophilic (odds ratio 5 1.19, P 5 .25) statins, statins plus nonstatins (odds ratio 5 1.95, P < .0001), and for the initial period after starting statins (<1 year odds ratio 5 1.82, 1-2.5 years odds ratio 5 1.75, and 2.5 years odds ratio 5 1.37; P trend < .0001). Conclusion: The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect. V C 2017 International Parkinson and Movement Disorder Society
Approximately 43 U.S. million adults receive or are eligible for statin therapy; this may increase based on new cardiovascular prevention guidelines and new generic statins. Several preclinical studies have suggested that statins may protect against Parkinson's disease (PD), [1] [2] [3] [4] [5] yet epidemiological findings on this relationship have been inconsistent: some reported lower PD risk among statin users, [6] [7] [8] but others no difference [9] [10] [11] [12] [13] or even higher risk. 14 The interpretation of these data, however, is not straightforward. First, a recent meta-analysis suggested a significant publication bias toward reporting protective effects of statins in PD. 15 Second, even in those studies reporting protective effects, the interpretation of the results is confounded by the use of statins for hyperlipidemia. 16 This is relevant because several case-control [10] [11] [12] and prospective studies 13, 17 suggest that higher serum/ plasma total and/or low-density liprotein (LDL)-cholesterol levels are related to lower occurrence of PD. Last, statins differ in their ability to cross the bloodbrain barrier, and the number of PD patients was too small in prior studies to allow stratification.
Despite this uncertainty, 14, 18 there has been a prevailing sentiment to use statins as neuroprotective agents [19] [20] [21] ; indeed simvastatin (a lipophilic statin) is in a current clinical trial. 19 It is, therefore, timely to evaluate carefully the relationship of statins and PD risk.
Methods Data Source
The MarketScan Commercial Claims and Encounters database (Truven Health Analytics, Ann Arbor MI) consists of individual reimbursed healthcare claim information from more than 130 payers describing the healthcare use and expenditures for >50 million employees and family members per year. Ages range from birth to 64 years, when most individuals switch from private insurance to Medicare. 22 Because PD is age related and mainly affects older adults, we limited our search to all individuals in the database who had 
PD Case Identification and Confirmation
Possible prevalent PD cases were identified using the following criteria: (1) primary or secondary diagnosis of PD (International Classification of Diseases ICD-9 332); (2) use of any anti-PD medication containing carbidopa/levodopa (Sinemet, Parcopa, Stalevo, Duodopa), pramipexole (Mirapex), ropinirole (Requip), pergolide (Permax), rotigotine (Neupro), entacapone (Comtan), selegiline (Eldepryl, Zelapar), rasagiline (Azilect), carbidopa (Lydosyn), or amantadine (Symmetrel); and (3) To ascertain incident PD patients, we narrowed our search to those prevalence cases that had a minimum of 2.5 years of continuous enrollment prior to the index date defined as the earliest PD indication by diagnosis or prescription of antiparkinson medication. This ensured a reasonable observation window. Controls were matched individually to cases by age, gender, and a follow-up window that was defined as the time from a patient's initial insurance coverage date during our study period to the index date of PD indication. The control in the matched pair must have had a follow-up window that was at least as long as the PD case. The matched control then was assigned the same index date as the matched patient case.
Ascertainment of Hyperlipidemia and Comorbidities
Although cholesterol may play a role in the hypothesized statin-PD association, cholesterol lab data were not included in the MarketScan database. Thus, we used the diagnosis of hyperlipidemia (272.0-272.4) as a surrogate marker of history of high cholesterol level. Statins can be prescribed for conditions other than hyperlipidemia, so we identified the following disorders by diagnosis codes (ICD-9 codes): hypertension (401), coronary artery disease (410), and diabetes (250).
Ascertainment of Statins and Other Cholesterol-Lowering Drug Usage
Statins and other cholesterol-lowering drug (ie, unspecified antihyperlipidemics, bile sequestrants, or fibrates) usage were defined as more than 2 separate prescriptions. Statins were subgrouped into hydrophilic (pravastatin, rosuvastatin) and lipophilic (atorvastatin, fluvastatin, lovastatin, pitavastatin, simvastatin). Fenofibrate, ezetimibe, and niacin were considered nonstatin cholesterol-lowering drugs. For the matched casecontrol analysis, we determined whether a patient had been prescribed statins and/or nonstatin cholesterollowering drugs. If so, we then calculated the statin exposure window as the period between the earliest date of a filed claim for a statin prescription and the index date. We categorized statin users into 3 groups according to the length of their statin exposure (ie, <1 year, 1-2.5 years, or 2.5 years) prior to the first PD indication.
Data Analysis

Cross-Sectional Analysis
We performed descriptive analyses on the entire study cohort, summarizing the cohort demographics (age, gender), comorbidities, and cholesterol-lowering drug use (statins and nonstatins). We then ran a multivariable logistic regression to assess the significance of the association between cholesterol-lowering drug use (vs nonuser as a reference) and prevalent PD, adjusting for age, gender, and comorbid diseases such as hyperlipidemia, diabetes, hypertension, and coronary artery disease. Cholesterol-lowering drugs were divided into statin only, nonstatin cholesterol-lowering drugs only, and the use of both statin and nonstatin cholesterol-lowering drugs.
Matched Incident Case-Control Analysis
We ascertained the usage of cholesterol-lowering drugs prior to index dates for PD cases and controls, and the statins were also analyzed based on their lipophilic or hydrophilic properties. We also categorized the earliest time of drug exposure epochs as <1 year, 1-2.5 years, or 2.5 years before the index date. We ran a conditional logistic regression to determine the significance of the associations between PD incidence and the earliest prior statin exposure (ie, <1 year, 1-2.5 years, or 2.5 years) in conjunction with or without the use of nonstatin cholesterol-lowering drugs. The analyses were adjusted for all of the aforementioned covariates except for age and gender that had been used for matching cases and controls.
All statistical analyses were performed using SAS version 9.3 software (SAS Institute, Cary, North Carolina). Statistical tests were 2-sided, with a .05 being statistically significant.
Results
Population Characteristics
Of the 30,343,035 individuals eligible for the analysis, a total of 21,599 patients met our prevalence case definition (Supplemental Table 1 ). As expected, PD patients were older and more likely to be men. PD prevalence was associated positively with age, male gender, hypertension, coronary artery disease, usage of cholesterol-lowering drugs (statins or nonstatins), and negatively with hyperlipidemia.
Case-Control Analysis of Prior Statin
Exposure and PD
Prior statin usage was associated significantly with higher PD risk (Table 1, Fig. 1 Fig. 1 ).
Discussion
Statin use was associated with higher, not lower, PD risk, and the association was more pronounced for lipophilic statins, an observation inconsistent with the current hypothesis that these statins are neuroprotective. [19] [20] [21] In addition, the statin-PD association was most robust for the initial phase of statin treatment (<2.5 years), suggesting that statins may facilitate the onset of preclinical PD. Because new guidelines 23 may lead to broader statin use, additional studies should assess the potentially adverse effect of statins (particularly lipophilic statins) on certain populations vulnerable to PD.
Although not unanimous, 24 the weight of the literature favors an association of high lipid cholesterol levels with lower risk of PD via both case-control 9, [25] [26] [27] [28] and prospective 14,29-31 studies. Our cross-sectional analysis of the Marketscan database (Supplemental Table 1 ) also found that the diagnosis of hyperlipidemia (a marker of high cholesterol) was associated with lower PD prevalence, consistent with the large majority of literature.
Most literature used data collected in the poststatin era, where hyperlipidemia would prime statin usage. Some reports have suggested lower PD risk among statin users, [6] [7] [8] 17 but none factored in this confound (ie, hyperlipidemia). Indeed, a recent meta-analysis reported that "protective effects" of statins disappear if hyperlipidemia is considered. 16 Moreover, prospective data from the Atherosclerosis in Community cohort showed that after accounting for total and LDL cholesterol levels, statin usage was associated with higher future risk of PD.
14 The current analysis also found that statin use was associated with higher PD risk after adjusting for all potential confounders, including hyperlipidemia.
We explored the timing of initial statin exposure relative to the earliest indication of PD onset. PD risk 
S T A T I N S A N D P D R I S K : A N O B S E R V A T I O N A L S T U D Y
was highest during the initial period after statin use (<2.5 years) compared to exposure further from PD diagnosis (2.5 years). Various environmental factors may trigger an otherwise dormant disease or medical condition, particularly in high-risk populations, and our data suggest that the statin-PD link may represent such a scenario. The large sample size in the current study also permitted estimation of associations with different statin types (lipophilic vs hydrophilic). In contrast to prior studies 17, 18 with much smaller sample sizes, we found that lipophilic statins were associated with highest PD risk. Conversely, a significant association was not found for nonstatin cholesterollowering agents, but the less frequent use of these drugs left this aspect of the study underpowered.
A recent study using the Taiwanese National Health Insurance NHI database reported that discontinuing statins (especially lipophilics) was more likely to lead to diagnosis of PD, 32 and this was interpreted as compelling evidence for neuroprotection. 17, 21 The current study, however, leads to an alternate interpretationstatins may have "unmasked" symptoms in those with pre-PD, 17 explaining why those patients discontinued statins. In the future, it is critical to obtain both diagnosis and lipid status for those discontinuing statins.
The study has several limitations. First, the claims data did not include Medicare, Medicaid, or the uninsured. Because it was based on private insurance, the population did not include individuals aged 65 years or older (the transition age to Medicare); hence we are unable to generalize our findings to older populations. We ascertained PD cases from the claims records alone, without having clinical details or case confirmation, and misdiagnosis may have occurred because of record entry, coding, and so on. To minimize diagnostic uncertainty, we required that PD cases had at least 2 separate criteria supporting the diagnosis. In addition, the claims data lacked lab values, preventing quantitative assessment of lipid cholesterol levels, something of importance for future studies. 
Supporting Data
Additional Supporting Information may be found in the online version of this article at the publisher's web-site. 
Striato-cortical Connections in
ABSTRACT
Background: Functional connectivity is abnormal in PD and in early Alzheimer's disease. Objectives: The objective of this study was to evaluate resting-state striato-cortical connectivity in PD and Alzheimer's disease and assess their relation to cognitive outcomes. Groups with mild cognitive impairment as a result of different pathologies (PD vs. Alzheimer's disease) were also compared. Methods: Seed-based connectivity of the dorsal, middle, and ventral striatum was analyzed in 111 patients using functional MRI. The correlation between connectivity at regions of between-group differences and clinical outcomes was assessed. Results: Patients showed lower striatal connectivity than controls. Connectivity between the middle (associative) striatum and precuneus negatively correlated with executive functions in PD and with memory performance in Alzheimer's disease. PD with cognitive impairment showed decreased connectivity of the dorsal (motor) striatum when compared with early Alzheimer's disease. Conclusions: Striatal connectivity was reduced in patients when compared with controls. Similar compensatory mechanisms were employed to overcome various cognitive deficits in PD and Alzheimer's disease. Some abnormalities in resting state functional connectivity (rs-FC) have been documented in both Alzheimer's disease (AD) and Parkinson's disease (PD), mainly in the default mode network. [1] [2] [3] [4] [5] [6] However, a recent meta-analysis reported additional rs-FC differences between patients with amnestic mild cognitive impairment (MCI) and healthy controls (HC) in regions of the cortico-striato-thalamic loop. 7 Previous studies have also shown a selective loss of cholinergic neurons and amyloid deposition in the ventral striatum of AD patients. 8, 9 Striatal rs-FC changes in PD patients were attributed to a loss of dopaminergic neurons that was related particularly to motor symptoms of PD. [10] [11] [12] A recent study showed that cognitive decline and motor deficit in PD are each associated with a differentiable pattern of rs-FC of striatal subregions (caudate and putamen). 13 Moreover, the study results demonstrated that specific striatal (caudate) rs-FC changes might reflect brain compensation strategies employed in an attempt to overcome cognitive deficits in PD. It is not known whether these patterns of brain changes are general and common for pathological aging caused by various pathologies or whether this is a unique mechanism for the PD population.
Therefore, we focused on subcortical-cortical rs-FC differences in both PD and AD-MCI when compared with HC. In addition, we studied the differences between PD-MCI and AD-MCI, that is, MCI groups caused by different pathologies. Moreover, we explored the associations between clinical variables and the rs-FC of specific subdivisions of the striatum parcellated according to the probabilistic tractography 
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